Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect
Xiaoqian Lan, Hongyan Zhuang, Pengfei Li · 2026
Read Adjunctive aripiprazole for amisulpride-induced hyperprolactinemia: a preliminary retrospective study showing no reversing effect by Xiaoqian Lan, Hongyan Zhuang, Pengfei Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219813.txt.
Description
Xiaoqian Lan, Hongyan Zhuang, and Pengfei Li report a negative result on a prescribing workaround for antipsychotic side effects in a 2026 study. The antipsychotic amisulpride raises prolactin, a hormone whose excess can disrupt periods, fertility, and bone health. Clinicians add aripiprazole, a drug with an opposite grip on the dopamine system, hoping it will pull prolactin back down, but proof for amisulpride specifically was missing.
Reviewing records from a psychiatric hospital between 2022 and 2025, the team compared prolactin levels in the week before patients started add-on aripiprazole with levels a week after. The average change was small and insignificant, and splitting the patients by sex or diagnosis changed nothing. Removing any patient from the analysis, one at a time, never altered the conclusion, so no outlier was driving the result. Until evidence arrives, the authors advise caution about expecting this combination to rescue patients from prolactin elevation.
Catalog record
| CREATOR | Xiaoqian Lan, Hongyan Zhuang, Pengfei Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |